Morphine vs Fentanyl in Neonates: Pain Management Protocol in Indian NICUs
Introduction to Neonatal Pain Management
The recognition that neonates, including extremely preterm infants, experience pain and that untreated pain has adverse physiological and neurodevelopmental consequences has fundamentally transformed neonatal intensive care practice over the past three decades. Neonates admitted to Indian NICUs undergo an average of 10 to 15 painful procedures per day during the first two weeks of life, including heel pricks, venipuncture, intubation, lumbar puncture, and chest tube insertion. Despite growing awareness, studies from Indian NICUs have shown that pain assessment and treatment remain inconsistent, with significant gaps between evidence-based guidelines and clinical practice.
Morphine and fentanyl are the two most commonly used opioid analgesics in neonatal practice. Each has distinct pharmacological properties that influence their clinical applications. The NNF and IAP have published guidelines on neonatal pain management that incorporate both pharmacological and non-pharmacological strategies. This article provides a detailed comparison of morphine and fentanyl with dosing protocols appropriate for the Indian NICU setting.
Pain Assessment in Neonates
Effective pain management begins with systematic pain assessment using validated tools. The NNF recommends regular pain assessment as the fifth vital sign in all NICU patients.
Recommended Pain Assessment Tools
| Tool | Parameters Assessed | Age Range | Use |
|---|---|---|---|
| NIPS (Neonatal Infant Pain Scale) | Facial expression, cry, breathing, arms, legs, alertness | Preterm to term | Procedural pain |
| PIPP-R (Premature Infant Pain Profile-Revised) | Gestational age, behavioral state, HR change, SpO2 change, brow bulge, eye squeeze, nasolabial furrow | 28-40 weeks GA | Procedural and ongoing pain |
| N-PASS (Neonatal Pain, Agitation and Sedation Scale) | Crying, behavior, facial expression, extremity tone, vital signs | Preterm to term | Ongoing pain and sedation assessment |
| CRIES | Crying, Requires O2, Increased vital signs, Expression, Sleeplessness | 32-60 weeks GA | Postoperative pain |
Pain assessment should be performed before and after painful procedures, every 4 to 6 hours in ventilated neonates, and whenever clinical signs suggest pain or distress. Documentation of pain scores and response to intervention should be standard practice in all Indian NICUs.
Pharmacology: Morphine vs Fentanyl
Comparative Pharmacokinetics
| Parameter | Morphine | Fentanyl |
|---|---|---|
| Potency (relative) | 1x | 50-100x |
| Onset IV | 5-15 minutes | 1-3 minutes |
| Duration (single dose) | 3-6 hours | 30-60 minutes |
| Half-life (preterm) | 9-20 hours | 6-32 hours |
| Half-life (term) | 6-8 hours | 1-6 hours |
| Metabolism | Hepatic glucuronidation (UGT2B7) | Hepatic CYP3A4 |
| Active metabolites | M6G (analgesic), M3G (neuroexcitatory) | None clinically significant |
| Protein binding | 20-35% | 80-85% |
| Histamine release | Significant | Minimal |
| Lipid solubility | Low | Very high |
Key Pharmacological Differences in Neonates
Morphine's metabolism is significantly impaired in preterm neonates due to immature hepatic glucuronidation (UGT2B7 enzyme activity). This results in a prolonged half-life of 9 to 20 hours in preterm infants compared to 6 to 8 hours in term neonates. The active metabolite morphine-6-glucuronide (M6G) has potent analgesic activity and accumulates in neonates with renal impairment, potentially contributing to prolonged sedation and respiratory depression.
Fentanyl is metabolized by CYP3A4, which is also immature in neonates but develops more rapidly than UGT2B7. Fentanyl's high lipid solubility leads to rapid distribution to the brain (fast onset) but also significant redistribution to peripheral tissues with repeated dosing, leading to accumulation and context-sensitive half-time prolongation with continuous infusions.
Dosing Protocols
Morphine Dosing
| Indication | Preterm (<32 weeks) | Late Preterm/Term | Route |
|---|---|---|---|
| Intermittent bolus | 0.025-0.05 mg/kg q4-6h | 0.05-0.1 mg/kg q4-6h | IV over 5 minutes |
| Continuous infusion | 5-10 mcg/kg/hour | 10-20 mcg/kg/hour | IV syringe pump |
| Loading dose (if needed) | 50 mcg/kg over 30 min | 100 mcg/kg over 30 min | IV infusion |
| Postoperative | 0.025-0.05 mg/kg q4h | 0.05-0.1 mg/kg q4h | IV bolus |
Fentanyl Dosing
| Indication | Preterm (<32 weeks) | Late Preterm/Term | Route |
|---|---|---|---|
| Procedural analgesia | 0.5-1 mcg/kg | 1-2 mcg/kg | IV slow push over 3-5 min |
| Continuous infusion | 0.5-1 mcg/kg/hour | 1-2 mcg/kg/hour | IV syringe pump |
| Intubation premedication | 1-2 mcg/kg | 2-4 mcg/kg | IV slow push |
| Postoperative | 0.5-1 mcg/kg q2-4h | 1-2 mcg/kg q2-4h | IV bolus |
Clinical Applications and Drug Selection
When to Choose Morphine
- Prolonged analgesia required (postoperative pain, ongoing painful conditions)
- Hemodynamically stable patient where mild hypotension is tolerable
- When oral transition is anticipated (morphine has better oral bioavailability)
- Neonatal Abstinence Syndrome (NAS) management with scheduled dosing
When to Choose Fentanyl
- Hemodynamically unstable patients (septic shock, cardiac surgery)
- Rapid-onset analgesia needed for procedures (intubation, chest tube insertion)
- Pulmonary hypertension (fentanyl does not increase pulmonary vascular resistance)
- When avoiding histamine release is important
- Short procedures where brief analgesia is desired
Adverse Effects and Safety
Common Adverse Effects
- Respiratory depression: Both drugs cause dose-dependent respiratory depression. Naloxone (0.1 mg/kg IV) should always be available when administering opioids to neonates.
- Hypotension: More common with morphine due to histamine release and venodilation. Ensure adequate volume resuscitation before morphine administration.
- Chest wall rigidity: Specific to fentanyl, particularly with rapid IV push. Administer fentanyl slowly over 3 to 5 minutes. Treatment includes naloxone and, if severe, neuromuscular blockade with assisted ventilation.
- GI effects: Both cause delayed gastric emptying, constipation, and feeding intolerance. Morphine has more pronounced GI effects.
- Urinary retention: Both drugs can cause urinary retention. Monitor urine output closely and consider bladder catheterization if oliguria develops.
Tolerance and Physical Dependence
Prolonged opioid infusion (typically beyond 5 to 7 days) leads to tolerance (requiring dose escalation) and physical dependence. Abrupt discontinuation after prolonged use can precipitate neonatal withdrawal symptoms including irritability, tremors, poor feeding, diarrhea, sneezing, and seizures. Gradual weaning is essential, with a standard approach of reducing the dose by 10 to 20 percent every 24 to 48 hours, guided by withdrawal scoring using the modified Finnegan score or Lipsitz tool.
Non-Pharmacological Pain Management
Non-pharmacological interventions should be used as first-line therapy for minor procedures and as adjuncts to pharmacological treatment for major procedures. These methods are particularly important in resource-limited Indian healthcare settings where opioid availability may be restricted.
- Oral sucrose 24%: 0.1 to 0.5 mL placed on the anterior tongue 2 minutes before the procedure. Effective for heel prick, venipuncture, and ROP screening. Evidence rated strong by Cochrane reviews.
- Non-nutritive sucking: Pacifier use during and after painful procedures. Combined with sucrose for additive analgesic effect.
- Kangaroo Mother Care (KMC): Skin-to-skin contact during procedures. Strong evidence from Indian studies supporting analgesic efficacy.
- Swaddling and facilitated tucking: Containing the infant in a flexed position reduces pain responses. Can be performed by nursing staff or parents.
- Breastfeeding: Direct breastfeeding during blood sampling provides analgesia comparable to oral sucrose.
Evidence from Major Trials
The NEOPAIN trial (2004) was a landmark study that raised important concerns about routine morphine infusion in ventilated preterm neonates. The trial found that routine morphine did not reduce the composite outcome of death, severe IVH, or PVL, and there was a trend toward worse outcomes in the most preterm infants. This has led to the current recommendation that opioids should be used selectively based on pain assessment scores rather than routinely in all ventilated neonates. Monitoring of opioid infusions with validated pain and sedation scales, integrated into HEAMAC clinical documentation systems where available, helps ensure rational use.
Practical Considerations for Indian NICUs
In government hospital NICUs in India, morphine injection (available as a Schedule H controlled substance) may face availability challenges due to opioid procurement regulations. Fentanyl, though also controlled, is often more readily available in operating theatres and can be obtained for NICU use. Establishing clear institutional protocols for opioid procurement, storage, administration, and documentation is essential. Non-pharmacological methods should be maximized in settings where pharmacological options are limited.
Conclusion
Effective neonatal pain management requires a multimodal approach combining systematic pain assessment, non-pharmacological interventions, and judicious use of pharmacological agents. Morphine and fentanyl each have distinct advantages and limitations in the neonatal population. The choice between them should be guided by the clinical situation, hemodynamic status of the infant, and practical availability in the specific healthcare setting. All Indian NICUs should have written pain management protocols and regular staff training to ensure that every neonate receives appropriate pain relief.